Through a clear focus on gastroenterology, Movetis seeks to improve the lives of millions of patients - both adults and children - by discovering, developing and ultimately commercializing innovative treatments targeting GI conditions with a high unmet medical need. Movetis NV - founded in Belgium in December 2006 - aims to become a leading European specialty pharmaceutical organization focused on GI diseases. Movetis has a broad GI portfolio with four products in clinical and four in preclinical development, all addressing important GI areas with fewer innovative products, including chronic constipation, ascites, reflux in infants, diabetic gastroparesis, non-erosive and refractory reflux disease and post-infectious IBS. In addition, Movetis owns a large library of qualified lead compounds for further development addressing GI disorders such as secretory diarrhoea. The current portfolio has been licensed from Janssen Pharmaceutica NV, Belgium and Ortho-McNeil Pharmaceutical Inc., two Johnson & Johnson (J&J) companies.
The current clinical portfolio includes:
- RESOLOR (prucalopride), a compound for the treatment of chronic
constipation currently in final preparation for filing.
- M0002, a selective V2 receptor antagonist compound for the treatment of
ascites that has concluded a Phase IIa trial. Results are expected
before the end of Q2 2008.
- M0003, a gastrokinetic compound for the treatment of reflux in infants
and symptoms of gastroparesis, which has entered a Phase IIa clinical
trial in Q1 2008. - M0004, another gastrokinetic compound for motility
complaints related to non-erosive or refractory gastro-oesophageal
reflux disease (GORD).
References
1. Camilleri M et al. Efficacy of 12-week treatment with prucalopride (Resolor(R)) in patients with chronic constipation: combined results of three identical randomized, double-blind, placebo-controlled phase III trials. Poster 435293, DDW 2008
2. Van Outryve MJ et al. Long-term follow-up study of oral prucalopride (Resolor(R)) administered to patients with chronic constipation. Poster 438541, DDW 2008
3. Tack JF et al. Safety and tolerability of prucalopride (Resolor(R)) in patients with chronic constipation: pooled data from three pivotal phase III studies. Poster 437976, DDW 2008
4. Boyce MJ et al. Cardiovascular safety of prucalopride (Resolor(R)) in healthy subjects: results from a randomized, double-blind, placebo-controlled, cross-over trial. Poster 430410, DDW 2008
5. Mueller-Lissner SA et al. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor(R)) in elderly patients with chronic constipation. Research Forum 438210, DDW 2008
6. Moulin DE et al. Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor(R)) in patients with opioid-induced constipation. Topic Forum 438068, DDW 2008
7. Galandiuk S. Evaluation of the efficacy, safety and tolerability of prucalopride (Resolor(R)) given subcutaneously in patients undergoing elective partial colectomies. Research forum 438293, DDW 2008
8. Drossman A. Rome III: The new criteria. Chinese Journal of Digestive Diseases 2006; 7 (4): 181-185.
9. IMS Health
10. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750-9
For further information contact Axon Communications: Vicki Martin, Tel: +44-208-439-9407, vmartin@axon-com.com; Sarah Griffin, Tel: +44-208-439-9582, sgriffin@axon-com.com
